⚠ Evidence warning: Clinical trials or other evidence do not support the claim that chaga cures or prevents cancer, including the folk report that chaga-drinking villages had less stomach cancer. This page keeps it as a report of what people, websites or other media say.

Chaga Mushroom Cancer Research

Cancer Research — scientific infographic poster

Honest framing first. Chaga (Inonotus obliquus) is not a cancer treatment. The widely circulated claim that chaga "cures cancer" — whether traced to Aleksandr Solzhenitsyn's 1968 novel Cancer Ward, to Russian folk-medical tradition, or to internet supplement marketing — is not supported by clinical evidence. What is supported: betulinic acid (a triterpenoid that chaga extracts from its birch host) induces apoptosis in several tumor cell lines in vitro, crude chaga extracts inhibit tumor growth in mouse tumor models, and a low gastric-cancer rate reported by tradition in birch-rich rural Russian villages may reflect a real (but currently unverifiable) traditional-diet contribution. What is missing: any rigorous randomized controlled trial in human cancer patients. This deep-dive walks through the historical context, the actual cell-culture and animal data, the proposed mechanisms (betulinic acid apoptosis induction, immunomodulatory anti-tumor activity, antioxidant cancer prevention), and what is known about chaga alongside cancer care.


Table of Contents

  1. Solzhenitsyn's Cancer Ward and the Russian Folk-Cancer Story
  2. The Russian Village Gastric-Cancer Observation
  3. A Licensed Russian Chaga Extract — The Russian Drug Listing
  4. Betulinic Acid Apoptosis Mechanism (In Vitro)
  5. Tumor Cell Line Data (Melanoma, Colon, Liver, Breast)
  6. Mouse Tumour Studies and Crude Extract Data
  7. The Immunomodulatory Anti-Tumor Pathway
  8. The State of Human Evidence (Honest Assessment)
  9. The Memorial Sloan Kettering Position and Why It Matters
  10. What Is Known About Chaga Alongside Cancer Care
  11. Key Research Papers
  12. Connections
  13. Featured Videos

Solzhenitsyn's Cancer Ward and the Russian Folk-Cancer Story

Aleksandr Solzhenitsyn's semi-autobiographical 1968 novel Cancer Ward (Rakovyy Korpus) drew on his own experience as a Soviet labor-camp survivor with cancer who, in 1954, was treated in a hospital in Tashkent, where his tumor went into remission. In one of the novel's recurring threads, characters discuss a peasant remedy from a Russian village — a black mushroom brewed as tea (chai chaga) — and the rumor circulating in the cancer ward that the peasant doctor "Maslennikov" has cured tumors in his rural practice with this remedy.

Solzhenitsyn's text is a literary device, not a medical claim, but the framing carried enormous weight. Cancer Ward was internationally famous; Solzhenitsyn received the 1970 Nobel Prize in Literature “for the ethical force with which he has pursued the indispensable traditions of Russian literature”, and the novel was widely read in the West at exactly the moment of growing Western interest in plant-derived cancer treatments (the early vinca alkaloid and taxane discoveries were happening in the same decade). The novel inspired the first wave of Western interest in chaga and the first wave of Soviet-era scientific investigation under Bulatov, Shashkina, and Yefimov at the Komarov Botanical Institute in Leningrad.

Two important caveats on the literary source:

  1. The "Maslennikov" peasant doctor character is fictional, though Solzhenitsyn based him loosely on real folk-medical practitioners he had heard about.
  2. Solzhenitsyn's own cancer went into remission after hospital treatment in Tashkent in 1954; that hospital experience, not a chaga cure, is what the novel draws on.

The fair reading is that Solzhenitsyn dramatized a real folk-medical tradition that had genuine cultural and historical roots, but the literary framing was not a medical endorsement, and the subsequent Western marketing claims that conflate the novel with clinical evidence are not justified.

Back to Table of Contents

The Russian Village Gastric-Cancer Observation

The substrate observation that gave rise to the Russian chaga tradition is genuinely interesting and harder to dismiss than the novel-derived claims. Rural birch-forest regions of Russia (the Komi-Permyak republic, parts of Karelia, parts of Western Siberia) are reported in the folk tradition to have had anomalously low gastric and stomach cancer rates compared to nearby urban or non-birch-region populations. No published registry data measuring or confirming this difference were found.

Three plausible explanations:

  1. Chaga consumption is genuinely protective — the strongest version of the traditional claim. Biologically plausible via the immunomodulatory and antioxidant mechanisms, but never confirmed by intervention trial.
  2. Confounding by lifestyle and environment — rural birch-forest populations differ from urban populations in many ways: lower processed-food intake, less industrial pollution, more physical activity, lower nitrosamine exposure (a known gastric carcinogen) from less industrial food processing. Any of these could account for the gastric cancer difference without chaga playing any role.
  3. Reporting and diagnostic differences — rural populations had less access to medical care, so gastric cancers may have been under-diagnosed in life and under-registered at death. This would deflate apparent rates without any actual protective effect.

Modern epidemiology has not been able to disentangle these explanations because the relevant Soviet-era records are incomplete, the populations have substantially urbanized since the 1970s, and a prospective trial of chaga consumption for gastric cancer prevention is not ethically or logistically feasible. The observation is reported, but neither its size nor its cause is established.

For more on gastric cancer epidemiology and risk factors, see our Gastroenterology category page.

Back to Table of Contents

A Licensed Russian Chaga Extract — The Russian Drug Listing

One concrete product of the Soviet-era chaga research is a licensed Russian chaga extract — a standardized aqueous extract of Inonotus obliquus formulated with small amounts of cobalt salts (its current label lists cobalt chloride/cobalt sulfate), approved as an over-the-counter pharmaceutical in the Soviet Union (and subsequently the Russian Federation). Its label lists sluggish (hypotonic) movement of the digestive tract, stomach and duodenal ulcer and chronic gastritis, as well as weakness (asthenic states), wasting (cachexia), the period after surgery and long-term immunosuppressive therapy. It remains available in Russian pharmacies today, sold without a prescription.

The label is more conservative than the surrounding folk-medical claims would suggest. Cancer is not among its indications; its special instructions say only that it may be used as part of combination therapy for tumour diseases “to improve blood formation and digestion”. The weakness and wasting indications are the closest the label comes to the folk-medical broader claim.

The extract's clinical track record (such as it is, mostly Russian-language and not subjected to Western regulatory standards) suggests reasonable safety in adult outpatient use at recommended doses over months. The Russian pharmacopeia listing is not equivalent to U.S. Food and Drug Administration (FDA) or European Medicines Agency (EMA) approval and does not constitute Western clinical-trial-grade evidence, but it does represent the institutional translation of the folk tradition into a regulated pharmaceutical form for a narrow indication.

Back to Table of Contents

Betulinic Acid Apoptosis Mechanism (In Vitro)

The most-studied anti-cancer mechanism for chaga is the activity of betulinic acid, a pentacyclic triterpenoid that chaga extracts from its birch host tree. Betulinic acid was identified as a melanoma-selective cytotoxic agent in a landmark 1995 Nature Medicine paper by Pisha and colleagues, working through bioassay-guided fractionation of plant material. Betulinic acid emerged as the active compound — tested as the purified compound, which the authors describe as “inexpensive and available in abundant supply from common natural sources, notably the bark of white birch trees”; in follow-up work in athymic mice carrying human melanoma xenografts, tumor growth was completely inhibited without observed toxicity. That mouse result is the strongest in vivo signal in this entire literature — but it is a result for purified betulinic acid given to mice, not for chaga tea drunk by people.

The proposed apoptosis mechanism involves several molecular events:

These in-vitro mechanisms are biologically real and have been replicated in multiple independent laboratories. The complication is that betulinic acid is poorly bioavailable orally (most of an oral dose is not absorbed) and the in-vitro effective concentrations (micromolar range) are difficult to achieve in vivo from realistic chaga consumption. No human trial of betulinic acid in cancer was found; the human trials of betulinic-acid derivatives that were found lie outside cancer, for example a phase I and II study of bevirimat, a betulinic-acid derivative, against human immunodeficiency virus (HIV) infection.

Back to Table of Contents

Tumor Cell Line Data (Melanoma, Colon, Liver, Breast)

Beyond the original melanoma findings, betulinic acid and crude chaga extracts have been tested against a wide range of human tumor cell lines, with reasonably consistent in-vitro cytotoxicity:

The breadth of in-vitro cytotoxicity is impressive and suggests that the betulinic acid mechanism (mitochondrial-pathway apoptosis induction in a p53-independent manner) is genuinely broad-spectrum. The in-vivo translation is the harder question.

Back to Table of Contents

Mouse Tumour Studies and Crude Extract Data

Mouse tumour studies — xenografts (where human tumor cells are implanted in immunocompromised mice and the tumor growth is tracked over weeks of treatment) and mouse tumours grown in ordinary mice — bridge the gap between cell-culture work and human clinical trials. Several have tested crude chaga extracts and purified compounds:

Three studies frequently cited in this section do not belong in it, and the correction matters. Lemieszek et al. (2011) is titled “in vitro studies” and contains no animal data at all — any tumor-volume percentage attributed to it is not in the paper. Burczyk et al. (1996) tested aqueous chaga extract on HeLa cervical cancer cells in culture, not in mice; there is no Ehrlich ascites experiment in it. Sun et al. (2008) measured blood glucose and lipid peroxidation in alloxan-diabetic mice and reports no tumor endpoint whatsoever. We have removed those three claims rather than repeat them, because in-vitro results dressed as in-vivo results are exactly how a modest mechanism becomes a marketing claim.

The honest interpretation of what animal data do exist: oral chaga extract inhibited tumor growth in mice — a 60% tumor reduction in the one oral whole-extract study (Arata 2016). That is a single study of a mouse tumour in mice, not a result in people. It is consistent with the multifaceted, low-affinity mechanism (beta-glucan immunomodulation plus betulinic acid apoptosis induction plus polyphenol antioxidant/Nrf2 signaling) and is not consistent with the marketing-claim level of "cancer treatment."

Back to Table of Contents

The Immunomodulatory Anti-Tumor Pathway

Beyond direct betulinic-acid cytotoxicity, chaga's anti-tumor potential operates through immunomodulation — activation of natural killer (NK) cells, tumor-associated macrophages, and cytotoxic T cells that recognize and kill tumor cells. This is the same mechanism that has been clinically successful for other medicinal mushroom polysaccharide preparations:

The mechanistic basis for these clinically successful mushroom polysaccharides is the same beta-glucan binding to Dectin-1, TLR-2/4, and complement receptor 3 that we discussed in the Immune Modulation deep-dive. The resulting natural killer cell activation, macrophage activation, and T-cell priming can contribute to anti-tumor surveillance.

Whether oral chaga consumption achieves clinically meaningful immune activation is the harder question. Lentinan is given intravenously; PSK is a purified, standardised polysaccharide taken by mouth, at 3 g a day in the colorectal trials. Oral consumption of variable wild-harvested chaga is an entirely different exposure profile.

So the analogy with clinically successful mushroom-derived cancer adjuvants is genuine but limited. Chaga's biologically plausible immune mechanism does not automatically translate to "chaga has the same effect as PSK" in clinical oncology.

Back to Table of Contents

The State of Human Evidence (Honest Assessment)

What we have:

What we do not have:

The intellectually honest position is that chaga has biologically plausible anti-tumor mechanisms supported by in-vitro and animal data, but the human evidence is preliminary and does not support specific clinical claims. In the context of cancer, the evidence supports describing chaga as a traditional adjunct with a plausible biological basis, not as an evidence-based cancer treatment.

For broader context on cancer treatment and prevention, see our Cancer page.

Back to Table of Contents

The Memorial Sloan Kettering Position and Why It Matters

Memorial Sloan Kettering Cancer Center (MSKCC) maintains a public herb-drug interaction database (the "About Herbs" project) that is widely consulted by oncology professionals. Their chaga entry is worth quoting because it represents the institutional position of one of the most respected cancer centers in the world:

MSKCC's chaga summary lists antitumor and other effects seen in preclinical studies, notes its use as a folk remedy in Russia and other northern European countries “to treat various ailments and diseases including cancer”, and states: “But the safety and efficacy of chaga have yet to be evaluated in clinical studies.” It lists these safety points:

The second kidney case is described in a 2020 Korean report: the 49-year-old man had taken chaga powder for years for severe (intractable) atopic dermatitis, and his kidney biopsy showed oxalate crystal deposits. The leftover chaga measured “14.2/100 g” oxalate, and his estimated daily oxalate intake was 2 times that of a usual diet for four years and 5 times for one year.

The MSKCC summary is representative of what mainstream Western oncology says about chaga: biologically plausible, traditionally used, not yet evaluated in clinical studies, and with several documented safety concerns. Its patient section asks people to tell their healthcare providers about any dietary supplements they take, because “This will help them manage your care and keep you safe.”

Back to Table of Contents

What Is Known About Chaga Alongside Cancer Care

What the sources above report for people with cancer who use chaga:

Back to Table of Contents

Key Research Papers

  1. Pisha E, Chai H, Lee IS, et al. (1995). Discovery of betulinic acid as a selective inhibitor of human melanoma that functions by induction of apoptosis. Nature Medicine 1(10):1046-1051. — PubMed PMID: 7489361
  2. Fulda S (2008). Betulinic acid for cancer treatment and prevention. International Journal of Molecular Sciences 9(6):1096-1107. — PubMed PMID: 19325847
  3. Fulda S, Friesen C, Los M, et al. (1997). Betulinic acid triggers CD95 (APO-1/Fas)- and p53-independent apoptosis via activation of caspases in neuroectodermal tumors. Cancer Research 57(21):4956-4964. — PubMed PMID: 9354463
  4. Lemieszek MK, Langner E, Kaczor J, et al. (2011). Anticancer effects of fraction isolated from fruiting bodies of chaga medicinal mushroom, Inonotus obliquus: in vitro studies. International Journal of Medicinal Mushrooms 13(2):131-143. — cell culture only; this paper contains no animal data. — PubMed PMID: 22135889
  5. Burczyk J, Gawron A, Slotwinska M, et al. (1996). Antimitotic activity of aqueous extracts of Inonotus obliquus. Bollettino Chimico Farmaceutico 135(5):306-309. — HeLa S3 cervical cancer cells in culture. — PubMed PMID: 8942059
  6. Youn MJ, Kim JK, Park SY, et al. (2009). Potential anticancer properties of the water extract of Inonotus obliquus by induction of apoptosis in melanoma B16-F10 cells. Journal of Ethnopharmacology 121(2):221-228. — PubMed PMID: 19041933
  7. Youn MJ, Kim JK, Park SY, et al. (2008). Chaga mushroom (Inonotus obliquus) induces G0/G1 arrest and apoptosis in human hepatoma HepG2 cells. World Journal of Gastroenterology 14(4):511-517. — PubMed PMID: 18203281
  8. Lee SH, Hwang HS, Yun JW (2009). Antitumor activity of water extract of a mushroom, Inonotus obliquus, against HT-29 human colon cancer cells. Phytotherapy Research 23(12):1784-1789. — PubMed PMID: 19367670
  9. Fan L, Ding S, Ai L, Deng K (2012). Antitumor and immunomodulatory activity of water-soluble polysaccharide from Inonotus obliquus. Carbohydrate Polymers 90(2):870-874. — PubMed PMID: 22840014
  10. Sun JE, Ao ZH, Lu ZM, et al. (2008). Antihyperglycemic and antilipidperoxidative effects of dry matter of culture broth of Inonotus obliquus in submerged culture on normal and alloxan-diabetes mice. Journal of Ethnopharmacology 118(1):7-13. — a glucose and lipid-peroxidation study; it reports no tumor endpoint — PubMed PMID: 18434051
  11. Arata S, Watanabe J, Maeda M, et al. (2016). Continuous intake of the chaga mushroom (Inonotus obliquus) aqueous extract suppresses cancer progression and maintains body temperature in mice. Heliyon 2(5):e00111. — an animal study, not a human one. — PubMed PMID: 27441282
  12. Najafzadeh M, Reynolds PD, Baumgartner A, et al. (2007). Chaga mushroom extract inhibits oxidative DNA damage in lymphocytes of patients with inflammatory bowel disease. BioFactors 31(3-4):191-200. — PubMed PMID: 18997282
  13. Zhao Y, Zheng W (2021). Deciphering the antitumoral potential of the bioactive metabolites from medicinal mushroom Inonotus obliquus. Journal of Ethnopharmacology 265:113321. — PubMed PMID: 32877719
  14. Miyake Y, Nishimura J, Kato T, et al. (2018). Phase III trial comparing UFT + PSK to UFT + LV in stage IIB, III colorectal cancer (MCSGO-CCTG). Surgery Today 48(1):66-72. — the PSK arm failed to show non-inferiority. — PubMed PMID: 28634730
  15. Ogawa H, Shiraishi T, Okada T, et al. (2024). Adjuvant chemotherapy with UFT/LV versus UFT/LV plus PSK in stage II/III colorectal cancer. Anticancer Research 44(2):805-814. — no significant difference in 3-year disease-free survival. — PubMed PMID: 38307591
  16. Nakazato H, Koike A, Saji S, et al. (1994). Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Lancet 343(8906):1122-1126. — PubMed PMID: 7910230
  17. Ohwada S, Ikeya T, Yokomori T, et al. (2004). Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer: a randomised controlled study. British Journal of Cancer 90(5):1003-1010. — PubMed PMID: 14997197
  18. Sakamoto J, Morita S, Oba K, et al. (2006). Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curatively resected colorectal cancer: a meta-analysis of centrally randomized controlled clinical trials. Cancer Immunology, Immunotherapy 55(4):404-411. — PubMed PMID: 16133112
  19. Kikuchi Y, Seta K, Ogawa Y, et al. (2014). Chaga mushroom-induced oxalate nephropathy. Clinical Nephrology 81(6):440-444. — PubMed PMID: 23149251
  20. Lee S, Lee HY, Park Y, et al. (2020). Development of end stage renal disease after long-term ingestion of chaga mushroom: case report and review of literature. Journal of Korean Medical Science 35(19):e122. — PubMed PMID: 32419395
  21. Smith PF, Ogundele A, Forrest A, et al. (2007). Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3′,3′-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection. Antimicrobial Agents and Chemotherapy 51(10):3574-3581. — PubMed PMID: 17638699

PubMed Topic Searches

  1. PubMed: Inonotus obliquus chaga cancer antitumor
  2. PubMed: Betulinic acid apoptosis tumor cell
  3. PubMed: Chaga gastric cancer Russian folk medicine
  4. PubMed: Medicinal mushroom adjuvant chemotherapy cancer survival
  5. PubMed: Betulinic acid intravenous phase I trials
  6. PubMed: Mushroom polysaccharide NK / anti-tumor immunity

Back to Table of Contents

Connections

Back to Table of Contents